A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis

This is a single center study. This is an open label study of fluocinonide cream 0.1%
(Vanos™) for subjects with mild to severe atopic dermatitis with an assessment of 2 to 4 on
the Investigator Global Assessment scale (Appendix B). Up to 20 subjects age 12 and above
will be enrolled after providing informed consent. All subjects will receive the study
medication, fluocinonide cream 0.1% (Vanos™). Each subject will be instructed to use
fluocinonide cream 0.1% (Vanos™) twice daily for three consecutive days (for a total of 6
doses). The study period will last for approximately 2 weeks. Subjects will be evaluated at
baseline and Day 2 or 3 (as needed to achieve 6 doses), day 7 and day 14 (or end of study).
Subjects will not apply any study drug after the 6 doses.

Inclusion Criteria:

- Male or female with mild to severe atopic dermatitis, 12 years of age or older, that
agree to participate and provide written consent (and assent if applicable)

- Have an Investigator Global Assessment of mild to severe atopic dermatitis (IGA rating
of 2 - 4 in the Investigator Global Assessment (Appendix B))

- Percentage of overall body surface are of involvement (BSA) must be ≥2%

- Women of child bearing potential will be allowed to participate in the study, and
these subjects will be required to use at least one form of birth control

Exclusion Criteria:

- Use within 4 weeks of baseline of systemic anti‐inflammatory medication, which may
influence study outcome, such as systemic corticosteroids

- Application or use within 2 weeks of baseline of topical corticosteroid medications or
topical anti‐inflammatory medication, which may influence study outcome

- Presence of a concurrent medical condition, which is determined by the investigator to
potentially interfere with study outcomes or patient assessments

- Introduction of any other prescription medication, topical or systemic, for atopic
dermatitis while participating in the study

- Amount of disease involvement that would require >60 gm of cream in a 1 week period

- Subjects with known allergy or sensitivity to topical Vanos™ cream or components

- Pregnant women and women who are breastfeeding are to be excluded. Women of
childbearing potential will be allowed to participate in the study, and these subjects
will be required to use at least one form of birth control.